• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $67 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-6 Mln

Medicinova Inc (MNOV) Share Price

$1.38

As on 04-Mar-2024 16:00 EST

up-down-arrow $0.032.22%

  • Prev Close info

    $1.35

  • Day's Openinfo

    $1.38

  • Today's Highinfo

    $1.42

  • Today's Lowinfo

    $1.37

  • Today's Volumeinfo

    14,712

  • 52 Week rangeinfo

    $1.26 - 2.66

Please wait...

Medicinova Inc (MNOV) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Medicinova (MNOV)
-8.00 -1.78 -22.47 -38.39 -37.27 -31.57 -4.56
S&P BSE Sensex*
1.99 2.21 6.99 23.19 13.16 15.36 13.26
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 04-Mar-2024  |  *As on 05-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Medicinova (MNOV)
-26.83 -23.51 -49.05 -21.96 -17.50 26.11 7.30
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Medicinova Inc (MNOV) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Medicinova Inc (MNOV)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Medicinova Inc (MNOV)

        Co-Founder, President, CEO & Executive Director

        Dr. Yuichi Iwaki M.D., Ph.D.

        Chief Medical Officer & Director

        Dr. Kazuko Matsuda M.D., M.P.H., Ph.D.

        Headquarters

        La Jolla, CA

        FAQs for Medicinova Inc (MNOV)

        The total asset value of Medicinova Inc (MNOV) stood at $ 66 Mln as on 31-Dec-23

        The share price of Medicinova Inc (MNOV) is $1.38 (NASDAQ) as of 04-Mar-2024 16:00 EST. Medicinova Inc (MNOV) has given a return of -37.27% in the last 3 years.

        Medicinova Inc (MNOV) has a market capitalisation of $ 67 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Medicinova Inc (MNOV) is 1.07 times as on 29-Feb-2024, a -0.64% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Medicinova Inc (MNOV) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Medicinova Inc (MNOV) and enter the required number of quantities and click on buy to purchase the shares of Medicinova Inc (MNOV).

        MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California. Address: 4275 Executive Square, La Jolla, CA, United States, 92037

        The CEO & director of Dr. Yuichi Iwaki M.D., Ph.D.. is Medicinova Inc (MNOV), and CFO & Sr. VP is Dr. Kazuko Matsuda M.D., M.P.H., Ph.D..

        The promoters of Medicinova Inc (MNOV) have pledged 0% of the total equity as on Sep-23.

        Medicinova Inc (MNOV) Ratios
        Return on equity(%)
        -12.93
        Return on capital employed(%)
        -12.89
        Debt-to-equity ratio
        0
        Dividend yield(%)
        --

        No, TTM profit after tax of Medicinova Inc (MNOV) was $-6 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $66.70 Mln
        • Revenue (TTM)revenue-information $1,000.00 Mln
        • Earnings (TTM) earning-information $-5.79 Mln
        • Cash date-information $51.00 Mln
        • Total Debt info $0.22 Mln
        • Insider's Holding 2.98%
        • Liquidity liquidity Moderate
        • 52 Week range week-range $1.26 - 2.66
        • Shares outstanding share-outstanding 49,046,200
        • 10 Years Aggregate:

          CFO: $-78.60 Mln

          EBITDA: $-120.10 Mln

          Net Profit: $-114.31 Mln

        About The Company

        • IPO Date 08-Feb-2005
        • Co-Founder, President, CEO & Executive Director Dr. Yuichi Iwaki M.D., Ph.D.
        • Chief Medical Officer & Director Dr. Kazuko Matsuda M.D., M.P.H., Ph.D.
        • Listing key-listing NASDAQ: MNOV
        • Country United States
        • Headquarters headquarters La Jolla, CA
        • Website website https://www.medicinova.com
        • Business

          MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral...  anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California. Address: 4275 Executive Square, La Jolla, CA, United States, 92037  Read more

        share-fund-plan-icon